Article
Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.
Clinical transplantation - 1 Apr 2023
Reininger Kevin A, Onyeaghala Guillaume, Anderson-Haag Teresa, Schladt David S, Wu Baolin, Guan Weihua, Dorr Casey R, Remmel Rory P, Mannon Roslyn, Matas Arthur J, Oetting William S, Stahler Paul, Israni Ajay K, Jacobson Pamala A
Abstract excerpt
Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post-transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post-transplant was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.